Jupiter Orphan Therapeutics Announces Submission of Investigational New Drug Application (IND) For Treatment Of Mucopolysaccharidosis Type-I

March 14, 2018

Responsive image

JUPITER, Fla., March 14, 2018 /PRNewswire/ — Jupiter Orphan Therapeutics, Inc. (“JOT”), Jupiter, FL, today announced that it had submitted its IND to the FDA on March 12, 2018 for Mucopolysaccharidosis Type-I (MPSI). This will be the first of several anticipated IND submissions in 2018…

Category: Precious Metals